Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2016-03-25 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a certified public accounting firm and addresses the effectiveness of internal control over financial reporting for the fiscal year ended December 31, 2015. The content includes auditor responsibilities, management responsibilities, and an audit opinion on internal control effectiveness. This matches the description of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. The document length is short but contains substantive audit opinion content, not merely an announcement or certification. Therefore, it is classified as an Audit Report / Information (AR).
2016-03-25 Chinese
2015年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2015 年度内部控制评价报告' which translates to '2015 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2015. The content includes detailed descriptions of internal control scope, evaluation criteria, defect classifications, and conclusions about the effectiveness of internal controls related to financial reporting and non-financial reporting. It also includes statements about the responsibilities of the board and management regarding internal control. The document is a standalone report focused on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR) as it covers internal control evaluation results and related audit opinions, but is not a full Annual Report (10-K). The document length is 4140 characters, which is relatively short but contains substantive content rather than just an announcement or certification. Therefore, it should be classified as an Audit Report / Information (AR). FY 2015
2016-03-25 Chinese
第八届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of 马应龙药业集团股份有限公司 regarding the approval of the 2015 Annual Report and related internal control evaluation report. It includes voting results and confirms compliance with legal and regulatory requirements. The document is short (859 characters) and serves as an announcement of the supervisory board's meeting decisions rather than the full annual report itself. It does not contain the full financial statements or detailed report content but rather the approval and summary of the report and internal control evaluation. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official announcement related to the annual report but not the report itself.
2016-03-25 Chinese
2015年年度报告
Annual Report Classification · 100% confidence The document is titled "2015 年年度报告" which translates to "2015 Annual Report". It contains detailed financial data including profit distribution, net profit, revenue, cash flow, and comprehensive management discussion and analysis sections. The document includes audited financial statements, mentions the audit firm and their unqualified opinion, and covers company business overview, financial performance, risk factors, and governance. The length is substantial (15,000 characters), and it is the full report, not just an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2015
2016-03-25 Chinese
2015年年度报告摘要
Annual Report Classification · 98% confidence The document is titled as the "2015 年年度报告摘要" which translates to "2015 Annual Report Summary". It contains detailed financial data for the year 2015, including net profit, revenue, assets, quarterly financial indicators, shareholder information, management discussion and analysis, and notes on accounting policies and changes. It also mentions an audit report with an unqualified opinion from an accounting firm. The content is comprehensive and covers the company's full-year financial performance and business overview, consistent with an Annual Report. The document length is 8278 characters, which is sufficient to contain substantive financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2015
2016-03-25 Chinese
关于洛芬待因缓释胶囊获得药物临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving approval for a clinical trial permit for a new drug. It details the drug's name, approval number, application details, and some background on the drug development and market. The document is short (1342 characters) and does not contain financial statements, earnings data, or regulatory certifications. It is an announcement of a regulatory approval related to drug development, not a financial report or management update. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a clinical trial approval, which does not fit other specific categories.
2016-03-08 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.